956385-05-0

956385-05-0 structure

Name: Pomaglumetad methionil
Chemical Name: (1R,4S,5S,6S)-4-[[(2S)-2-amino-4-methylsulfanylbutanoyl]amino]-2,2-dioxo-2λ6-thiabicyclo[3.1.0]hexane-4,6-dicarboxylic acid,hydrate
CAS Number: 956385-05-0
Molecular Formula: C₁₂H₂₀N₂O₈S₂
Molecular Weight: 384.42600
Catalog: Signaling Pathways GPCR/G Protein mGluR
Create Date: 2016-07-25 03:20:32
Modify Date: 2025-08-27 13:05:41
Pomaglumetad methionil (LY2140023 hydrate) is an oral methionine prodrug of the potent specific mGlu2/3 receptor agonist LY404039 (HY-50906). Pomaglumetad methionil is well-tolerated and has a distinct safety profile, and can be used to treat schizophrenia[1][2].

Name	(1R,4S,5S,6S)-4-[[(2S)-2-amino-4-methylsulfanylbutanoyl]amino]-2,2-dioxo-2λ6-thiabicyclo[3.1.0]hexane-4,6-dicarboxylic acid,hydrate
Synonyms	Pomaglumetad methionil UNII-WE665JB15R

Description	Pomaglumetad methionil (LY2140023 hydrate) is an oral methionine prodrug of the potent specific mGlu2/3 receptor agonist LY404039 (HY-50906). Pomaglumetad methionil is well-tolerated and has a distinct safety profile, and can be used to treat schizophrenia[1][2].
Related Catalog	Signaling Pathways >> GPCR/G Protein >> mGluR Research Areas >> Neurological Disease
Target	mGlu2/3 receptor[1][2]
References	[1]. Adams DH, et al. A long-term, phase 2, multicenter, randomized, open-label, comparative safety study of pomaglumetad methionil (LY2140023 monohydrate) versus atypical antipsychotic standard of care in patients with schizophrenia. BMC Psychiatry. 2013 May 22;13:143. [2]. Downing AM, et al. A Double-Blind, Placebo-Controlled Comparator Study of LY2140023 monohydrate in patients with schizophrenia. BMC Psychiatry. 2014 Dec 10;14:351.